MA-VERISTAT
22.10.2020 10:15:06 CEST | Business Wire | Press release
Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.
Veristat , a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat’s experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.
“We understand how high the stakes are with cell and gene therapy programs,” stated Alecia Barbee, Executive Vice President, Operations at Veristat, “and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly.”
Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:
- The ability to develop your therapeutic with accelerated approval pathways and/or special designations
- A review of operational aspects of the protocol and feedback on any potential obstacles/challenges that could impact the protocol execution at the clinical research sites
- Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
- Expertise in logistics and handling of live cellular material
- Development of bespoke regulatory strategies for the type of cell and gene therapy and the unmet clinical need acceptable to the regulatory agencies
- Long-term follow-up strategies to meet global regulatory requirements
“The challenges of developing cell and gene therapies requires a committed and experienced partner,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide.”
About Veristat:
Veristat , a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005181/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“Moutai Night” Makes Seoul Debut, Celebrating China–South Korea Cultural Exchange3.11.2026 14:17:00 CET | Press release
On October 25, the 2026 “Moutai Night” was held in Seoul, South Korea, under the theme “Born by the Chishui River, Fragrance Along the Han River.” Over a hundred guests from China and South Korea gathered around the Han River, sharing the distinctive appeal of Chinese baijiu, and fostering cultural exchange between the two countries through fine liquor and culture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103333206/en/ “Moutai Night” Makes Seoul Debut, Celebrating China–South Korea Cultural Exchange The event featured an exhibition on Moutai’s brewing techniques and brand history. Hands-on experiences with Miao batik and silverwork showcased Guizhou culture, while creative cocktails brought Chinese spirits into dialogue with Korean tastes. A city-themed video, dance performances and a violin performance rounded out the program, as guests exchanged views on liquor culture in a warm atmosphere. As a flagship cultural
TVS Motor Company Strengthens Its European Presence With Four Production-Ready Models at EICMA 20263.11.2026 14:14:00 CET | Press release
TVS Motor expands its European presence through dedicated engineering facilities, a strengthened retail network and products developed for local customer needs Four production-ready models broaden the company's offering across electric mobility, premium urban transportation and lightweight sports motorcycling Global manufacturing scale, technology expertise and international engineering capabilities provide the foundation for TVS Motor's long-term success in Europe TVS Motor Company, the world's third-largest two-wheeler manufacturer, today unveiled four production-ready models at EICMA 2026 in Milan, reinforcing its commitment to Europe as a strategic market. The showcase highlights products developed for European customers, supported by dedicated engineering capabilities, an expanding retail network, and the strengths of TVS Motor's global manufacturing, technology and product development ecosystem. This press release features multimedia. View the full release here: https://www.busin
Teamily AI Reports 32× Quarterly User Growth, Positive Gross Margins, and Strong Global Adoption of Human–Agent Collaboration3.11.2026 14:00:00 CET | Press release
The AI-native collaboration platform reaches 320,000 users across 100+ countries, validates product-led growth and monetization, and prepares to expand its global AI agent ecosystem. Teamily AI, a human–agent collaboration platform that enables people and AI agents to work together in a unified, context-aware workspace, today announced significant growth and commercial milestones following a quarter of rapid global expansion. The company grew from 10,000 to 320,000 sign-ups in a single quarter, a 32× increase that works out to a compound monthly growth rate of 217.5%, just three months after its public launch in July 2026. With positive gross margins on paying users, and growing adoption among professional teams and businesses, Teamily AI establishes a foundation for scalable product-led growth (PLG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103047955/en/ 32× Global Growth in One Quarter Teamily AI grew from 10,000
Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 13:40:00 CET | Press release
One provider for identity, compliance and fraud prevention across 50+ countries, with a single integrated platform. Fourthline and Veridas combined will create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US; on track for 200 million verifications in 2026. With a projected combined revenue of more than €50m in 2026 and both businesses EBITDA-positive at closing, the company expects to reach €85m annual recurring revenue in 2029. Financials: The transaction includes funding of up to €65m provided by existing shareholder Finch Capital, new equity investment from Seaya Andromeda and debt financing from Ashgrove Capital. Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full rele
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release
Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
